Although the findings from early-phase PCSK9 inhibitor studies in small myocardial infarction cohorts were inconclusive, the potential impact on AIS receiving mechanical thrombectomy (MT) is anticipated, especially considering the direct relationship between final infarction volume and functional outcomes in AIS. Here, PCSK9 is linked to myocardial infarction.